Markets
← Back to Stocks
DVA
DAVITA INC
Health Care · Health Care Services
$149.84
+0.33%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Upbeat earnings and strong kidney dialysis demand lifts DaVita shares on analyst price target increases.
DaVita surged on upbeat Q4 2025 earnings and fiscal 2026 guidance, with stronger-than-expected results driven by steady demand for kidney dialysis services. The company raised price targets across multiple analysts (Truist to $158, UBS to $190, TD Cowen to $144), signaling confidence in the core dialysis business. Pre-market stock down 0.39% to $152.46 USD, showing some pullback from after-hours gains.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$10.0B
P/E (TTM)15.8
Forward P/E9.2
Beta0.93
Div Yield—
Prev Close$149.34
RSI (14-Day)
38Neutral
0305070100
52-Week Range
$101.00$149.84$159.42
From High-6.0%
From Low+48.4%
Moving Averages
50d SMA
$134.08+11.8%
200d SMA
$131.22+14.2%
Price above both MAs — bullish structure.
Returns
1W
-2.1%
1M
+1.4%
3M
+27.1%
6M
+17.1%
1Y
+0.3%
YTD
+30.9%
Volume
Today20K
20d Avg867K
Ratio0.02x